Peli BioThermal, a provider of temperature-controlled packaging solutions based in the United Kingdom, has announced the launch of its latest service centre in Ahmedabad, India, a significant production hub for pharmaceutical businesses in the western region of the country.
The new location is a full-service network station that provides conditioning and refurbishing services for Peli BioThermal’s Crdo Cargo and Crdo Xtreme bulk shippers in attempt to reach the region’s growing demand for the company’s Crdo on Demand rental programme.
“This is the most recent addition to our fast expanding Crēdo on Demand rental business.” “Ahmedabad is a critical location where more than eight of India’s leading pharmaceutical companies have several factories running, all of which are major exporters to markets in Europe and the United States,” said Dominic Hyde, Vice President – Global Services, Peli BioThermal.
“Our market-leading, high-performance products will be readily available for our clients in the region,” Hyde continues, “which is an area of considerable growth for various Clinical Research Organisations conducting clinical trials, which is another area of growth in India.” Peli BioThermal’s new India service centre is the latest addition to our growing global network of drop points, service centres, and network stations, which support rental programmes in over 100 locations as we continue to extensively expand our infrastructure globally to better meet the complex needs of our international customers.”
Ahmedabad is home to a growing number of renowned pharmaceutical businesses, including Astra Zeneca, Swiss Pharma, and Torrent Pharma. Ahmedabad, which is served by an international airport, is an important economic hub where several pharmaceutical companies have R&D facilities to launch new medicines to the market.
The state of Gujarat, where Ahmedabad is located, is believed to account for around 30% of the country’s pharmaceutical output and exports. Within the global pharmaceutical market, India supplies more than half of the global demand for various vaccinations and 40% of the demand for generic pharmaceuticals in the United States.
Peli BioThermal’s new India plant is the most recent addition to the company’s continuous initiatives to build new service centres to support its expanded services, further expanding its already extensive and unparalleled global network.